Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Anti-hIAPP for the preservation of pancreatic function in Type 2 Diabetes

Award Number: R44DK135154
ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/22/2022
PERIOD OF PERFORMANCE END DATE: 01/31/2026

Group Awards By:

View Award Description

Anti-hIAPP for the preservation of pancreatic function in Type 2 Diabetes - Project Summary According to the American Diabetes Association, Type 2 diabetes mellitus (T2D) affects at least 30 million Americans and is a major unmet public health concern with an annual cost in the United States of over $300 billion dollars. Additionally, nearly 25% of the U.S. population is already considered prediabetic, or at high risk of developing T2D. These individuals are characterized by poor glycemic control as a result of insulin resistance combined with reduced insulin secretion in response to glucose stimulation. At the prediabetic or early diabetic stages, insulin insufficiency is frequently managed by medications that stimulate pancreatic secretion, which is accompanied by increased levels of human islet amyloid polypeptide, hIAPP (amylin). Native hIAPP in its monomeric form is a hormone that inhibits glucagon secretion, delays gastric emptying, and acts as a satiety agent. However, when hIAPP misfolds, which is common at elevated production, it results in structures called protofibrils. These protofibrils are soluble, highly toxic, and capable of inducing cell death. The stimulated co- secretion of hIAPP with insulin leads to a pathologic cycle of increased hIAPP, including misfolded hIAPP, that leads to β cell toxicity in prediabetics and diabetics. The ensuing deficits in β cell function drive an increased need for insulin secretion, which is accompanied by further hIAPP secretion. In this sense, T2D is an amyloid- induced disease as evidenced by the presence of hIAPP plaque deposits in the pancreata of more than 90% of T2D patients. Developing new therapeutic strategies that target toxic hIAPP protofibrils, inhibit their deposition as toxic amylin fibrils, and ultimately preserve β cell health is a priority for addressing this major unmet need in T2D. Current standard-of-care in T2D is able to provide some control of blood glucose levels, but it fails to address the ? cell decline and its contribution to T2D progression. In this application we propose to advance a novel therapeutic platform and our lead product from that platform, CM-TS1. CM-TS1 is a monoclonal antibody that specifically targets protofibrils, soluble conformations of hIAPP for rapid clearance prior to plaque deposition and ? cell destruction. We have already demonstrated that CM-TS1 is capable of binding to these soluble protofibrils in peripheral blood and in the pancreata of a T2D murine model. We will continue therapeutic development by first validating our initial finding by demonstrating that CM-TS1 can clear hIAPP in an industry standard preclinical model leading to a reduction of T2D pathology. Following this in vivo proof-of-concept, we will then advance CM- TS1 through humanization and into early preclinical development including manufacturability, stable cell line construction, and non-GLP pharmacokinetic and toxicity studies ultimately culminating in a pre-IND Type B meeting with the FDA. The milestone of ultimate success will be launching this promising product into future IND-enabling studies in order to successfully reach the patients that need it the most.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2026 ( Subtotal = -$205 )
2026	2024	CELDARA MEDICAL, LLC	16 CAVENDISH CT STE 240	LEBANON	NH	03766	GRAFTON	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	3	5/13/2026	NON-COMPETING CONTINUATION	-$205
														Subtotal = -$205

Issue Date FY: 2025 ( Subtotal = $0 )
2025	2024	CELDARA MEDICAL, LLC	16 CAVENDISH CT STE 240	LEBANON	NH	03766	GRAFTON	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	001	3	7/3/2025	NON-COMPETING CONTINUATION	$0
2025	2022	CELDARA MEDICAL, LLC	16 CAVENDISH CT STE 240	LEBANON	NH	03766	GRAFTON	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	2/12/2025	NEW	$0
														Subtotal = $0

Issue Date FY: 2024 ( Subtotal = $999,828 )
2024	2024	CELDARA MEDICAL, LLC	16 CAVENDISH CT STE 240	LEBANON	NH	03766	GRAFTON	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	3	7/31/2024	NON-COMPETING CONTINUATION	$999,828
														Subtotal = $999,828

Issue Date FY: 2023 ( Subtotal = $1,031,510 )
2023	2023	CELDARA MEDICAL, LLC	16 CAVENDISH CT	LEBANON	NH	03766	GRAFTON	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	003	2	9/8/2023	EXTENSION WITH OR WITHOUT FUNDS	$999,432
2023	2022	CELDARA MEDICAL, LLC	16 CAVENDISH CT	LEBANON	NH	03766	GRAFTON	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	001	1	1/18/2023	NEW	$32,078
2023	2022	CELDARA MEDICAL, LLC	16 CAVENDISH CT	LEBANON	NH	03766	GRAFTON	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	002	1	2/8/2023	NEW	$0
2023	2022	CELDARA MEDICAL, LLC	16 CAVENDISH CT	LEBANON	NH	03766	GRAFTON	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	10/21/2022	NEW	$0
														Subtotal = $1,031,510

Issue Date FY: 2022 ( Subtotal = $267,818 )
2022	2022	CELDARA MEDICAL, LLC	16 CAVENDISH CT	LEBANON	NH	03766	GRAFTON	USA	Diabetes, Digestive, and Kidney Diseases Extramural Research	000	1	9/22/2022	NEW	$267,818
														Subtotal = $267,818

Grand Total All Awards = $2,298,951

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Anti-hIAPP for the preservation of pancreatic function in Type 2 Diabetes

Award Number: R44DK135154

ORGANIZATION: NATIONAL INSTITUTE OF DIABETES & DIGESTIVE & KIDNEY DISEASES

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/22/2022

PERIOD OF PERFORMANCE END DATE: 01/31/2026

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer